As reported
in a variety of news outlets yesterday, the shortage of H1N1 flu
vaccine has now become obvious. Throughout the country, many of those
lining up to be vaccinated are being turned away.
Why is
vaccine in short supply? Explanations are emerging slowly from the
Department of Health and Human Services (HHS). HHS Secretary Kathleen
Sebelius was one of three cabinet officers testifying
on October 21 before the Senate Committee on Homeland Security and
Governmental Affairs. She blamed the shortage of vaccine in part on
manufacturing delays, which she said have been corrected.
She
also confirmed that the U.S. is dependent on foreign manufacturers for
much of its vaccine and said this country needs to enhance its domestic
manufacturing capacity in the future. Several senators asked whether,
during the present pandemic, supplies of vaccine we expect from abroad
might instead be retained within their home countries. Secretary
Sebelius responded that the U.S. is “at the front of the line” with
orders it had placed with foreign manufacturers. However, she did not
comment on the possibility, raised by committee chairman Joseph
Lieberman, that the government of a foreign country might require its
vaccine manufacturers to fill its own needs first.
America’s
dependence on foreign sources of vaccine is just one of many
shortcomings that seriously detract from the strengths of the U.S.
government’s program for producing vaccine in a pandemic. POGO – in
letters to the Secretary of HHS, articles, and other public documents
for more than 18 months – has urged a comprehensive disclosure of
weaknesses in the vaccine program. Our documents identified specific
weaknesses that could lead to a shortage of vaccine in a pandemic.
On September 30, POGO sent its most recent letter, with an attached article, to Secretary Sebelius. In these documents and others linked to them we urge greater transparency in the vaccine program.
-- Ned Feder